ITRM - Iterum Therapeutics plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
0
0
0
0
37
Operating Expenses
Research Development
15,479
17,617
10,712
21,074
90,774
Selling General and Administrative
13,807
12,766
13,825
11,052
11,284
Total Operating Expenses
29,286
30,383
24,537
32,126
102,058
Operating Income or Loss
-29,286
-30,383
-24,537
-32,126
-102,021
Interest Expense
3,213
2,361
5,553
15,097
861
Total Other Income/Expenses Net
-10,656
-11,389
-60,769
-1,192
196
Income Before Tax
-43,155
-44,133
-90,859
-51,263
-102,686
Income Tax Expense
371
301
705
743
444
Income from Continuing Operations
-43,526
-44,434
-91,564
-52,006
-103,130
Net Income
-43,526
-44,434
-91,564
-52,006
-103,130
Net Income available to common shareholders
-43,526
-44,434
-91,564
-52,006
-103,130
Basic EPS
-
-3.63
-8.41
-32.49
-106.50
Diluted EPS
-
-3.63
-8.41
-32.49
-106.50
Basic Average Shares
-
12,237
10,891
1,601
967.869
Diluted Average Shares
-
12,237
10,891
1,601
967.869
EBITDA
-
-30,383
-85,306
-36,166
-101,825